ONCOINVENT & RADSPHERIN® - A Novel Alpha-Emitting and Non-Systemic Radiopharmaceutical Concept n Clinical Development

New Webinar with CEO of Oncoinvent AS - Anders Månsson 
  
We are thrilled to invite you to an exclusive webinar on November 22nd, featuring the CEO of Oncoinvent AS, Anders Månsson.   

Anders Månsson  is a highly experienced professional in the global healthcare and life sciences industry, with over 30 years of experience in senior-level positions at large multinational companies and smaller biotech startups. He has also worked as an industrial advisor to a large private equity firm in the life sciences field, and he is currently a partner and board member in a seed capital investment firm.  

In his upcoming presentation, Anders will provide a deep dive into the innovative world of Oncoinvent and Radspherin®, a novel alpha-emitting and non-systemic radiopharmaceutical pipeline under clinical development. He will discuss the groundbreaking potential of Radspherin® and its potential to revolutionize the treatment of cancer. 
  
About Oncoinvent 
Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells.  

Oncoinvent’s lead candidate, Radspherin®, is designed for treatment of metastatic cancers in body cavities, and its versatility allows it to be deployed for the treatment of a variety of cancer indications. Radspherin® is in two ongoing clinical studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer. 

Date: November 22, 2023  
Time: 9:00 PM BJT / 8:00 AM ET  
Moderator: Marc Estigarribia, MD of MSQ Ventures   

Can’t attend live? Register anyway, and we’ll send you the session recording after the event. Following the webinar, attendees will also have the chance to schedule a one-on-one session with BiOneCure through MSQ.